Stock chart
Analyses on Clal BIO Techno (4)
- March 24, 2026March 24, 2026
- Follow-up
Clal Biotech: Has Pi-Cardia Moved From Clearance To Market Proof
Pi-Cardia has already moved from a regulatory option to a funded commercialization option, but Clal Biotech’s filing still does not treat it as full market proof: there is clearance, first commercial use, and financing, yet the value recorded for the holding remains small and ev…
- Follow-up
Clal Biotech: What Is Actually Left In Colospan After The MOU And Lock-Up
Colospan’s MOU did not open new upside for CBI. It set a limited rescue value: a small group slice, mostly in locked stock, which already served as the basis for an NIS 11.1 million write-down.
- Follow-up
Clal Biotech: How Much Of MediWound’s Value Is Really Accessible After The Share-Retention Rule And The Loan
MediWound’s value is real and larger than CBI’s debt, but as long as the Access loan is still outstanding only about one-third of the position is available for a first sale, so the discount is mainly a sequencing and financing issue rather than an absence-of-value issue.
Clal Biotech 2025: MediWound Holds The Value, But Cash Holds The Risk
CBI trades at a real discount to the economic value embedded in MediWound, but until the parent-level liquidity and debt path is resolved that gap remains only partly accessible to common shareholders.
